“We are truly honored to be awarded with a Red Dot Design Award for the second year in a row. It is a result of great persistence and teamwork within our team at CELLINK. This quality stamp triggers us to enhance our design and usability focus even more into the market of laboratory equipment” says Markus Grip, Global Head of Design, CELLINK.
About BIO X6
With six printheads in total for unparalleled versatility, this innovative 3D bioprinter makes it easier to produce more complex and sophisticated constructs with a broader range of materials, cells and crosslinking tools. With many possible combinations, the six slots significantly increase throughput, cut down on print time and improve experiment efficiency. The BIO X6 is the preferred system for researchers seeking to enhance 3D cell culturing, tissue engineering, disease modelling and drug screening applications. More information about the product: https://www.cellink.com/bioprinting/bio-x6-3d-bioprinter/
About Red Dot Design Award
In 2021, designers and companies from all over the world entered with thousands of products in the competition. The international jury comprises experienced experts from different disciplines and has been convening for over 60 years. The jurors test all the entries in order to assess not just the aesthetic but also the materials selected, the level of craftsmanship, the surface structure, ergonomics, and functionality. After intensive discussions, they decide on the design quality of the products. True to the motto “In search of good design and innovation,” only the best designs receive an award.
For more information, please contact:
Isabelle Ljunggren, Head of Communications CELLINK
Phone: +46 708-30 08 90
The information was submitted for publication, through the agency of the contact person set out above, on March 23, 2021 at 14:00 (CET).
Founded in 2016, CELLINK is the leading bioconvergence company in the world that provides technologies, products and services to create, understand and master biology. With a focus on the application areas of bioprinting, multiomics, cell line development, and diagnostics, the company develops and markets innovative technologies that enable researchers in the life sciences to culture cells in 3D, perform high-throughput drug screening and print human tissues and organs for the medical, pharmaceutical, and cosmetic industries. CELLINK’s products are trusted by more than 1,800 laboratories, including ones at all the top 20 pharmaceutical companies, are being used in more than 65 countries, and have been cited in more than 1,600 publications. CELLINK is creating the future of medicine. CELLINK is listed on the Nasdaq the Stockholm under CLNK B. www.cellink.com